Back to top

Image: Bigstock

CVS Health (CVS) Down 0.9% Since Last Earnings Report: Can It Rebound?

Read MoreHide Full Article

It has been about a month since the last earnings report for CVS Health (CVS - Free Report) . Shares have lost about 0.9% in that time frame, outperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is CVS Health due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

How Have Estimates Been Moving Since Then?

It turns out, estimates revision have trended upward during the past month.

The consensus estimate has shifted 15.68% due to these changes.

VGM Scores

At this time, CVS Health has a poor Growth Score of F, a grade with the same score on the momentum front. However, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, CVS Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

CVS Health belongs to the Zacks Medical Services industry. Another stock from the same industry, Cencora (COR - Free Report) , has gained 4.7% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.

Cencora reported revenues of $81.49 billion in the last reported quarter, representing a year-over-year change of +12.8%. EPS of $3.73 for the same period compares with $3.28 a year ago.

For the current quarter, Cencora is expected to post earnings of $4.07 per share, indicating a change of +7.1% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.2% over the last 30 days.

Cencora has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


CVS Health Corporation (CVS) - free report >>

Cencora, Inc. (COR) - free report >>

Published in